medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Title

Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank

Authors

Xikang Fan[1 *], Cheng Yin[2 *], Jiayu Wang[1], Mingjia Yang[1], Hongxia Ma[1,3,4], Guangfu Jin[1,3,4], Mingyang Song[5,6,7], Zhibin Hu[1,3,4], Hongbing Shen[1,4], Dong Hang[1,4]

[*] Co-first authors, contributed equally.

Affiliations

[1] Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 211166;

[2] Department of Laboratory, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing, China, 211100;

[3] State Key Laboratory of Reproductive Medicine, Center for Global Health, Nanjing Medical University, Nanjing, China, 211166;

[4] Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China, 211166;

[5] Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 02115;

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

[6] Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 02115;

[7] Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, 02114.

Short title: IGF-1 and COVID-19 mortality

Keywords: IGF-1, COVID-19, SARS-CoV-2, coronavirus infection, mortality, UK Biobank

Correspondence:

Dong Hang, PhD

Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Center for Global Health, School of Public Health, Nanjing Medical University, 101 Longmian Avenue, Nanjing 211166, China.

Email: hangdong@njmu.edu.cn

ORCiD numbers: 0000-0001-6944-0459 (D. Hang).

Funding

This study was funded by National Natural Science Foundation of China (81820108028, 81521004, and 81973127), National Key R&D Program of

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

China (2016YFC1000200 and 2017YFC0908300), and Science Foundation for Excellent Young Scholars of Jiangsu (BK20190083). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosure Summary: The authors have nothing to disclose.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Background: Coronavirus disease 2019 (COVID-19) deteriorates suddenly primarily due to excessive inflammatory injury, and insulin-like growth factor-1 (IGF-1) is implicated in endocrine control of the immune system. However, the effect of IGF-1 levels on COVID-19 prognosis remains unknown.

Objective: To investigate the association between circulating IGF-1 concentrations and mortality risk among COVID-19 patients.

Design: Prospective analysis.

Setting: UK Biobank.

Participants: 1425 COVID-19 patients who had pre-diagnostic serum IGF-1 measurements at baseline (2006-2010).

Main outcome measures: COVID-19 mortality (available death data updated to 22 May 2020). Unconditional logistic regression was performed to estimate the odds ratio (OR) and 95% confidence intervals (CIs) of mortality across the IGF-1 quartiles.

Results: Among 1425 COVID-19 patients, 365 deaths occurred due to COVID-19. Compared to the lowest quartile of IGF-1 concentrations, the highest quartile was associated with a 37% lower risk of mortality (OR: 0.63, 95% CI: 0.43-0.93, *P*-trend=0.03). The association was stronger in women and nonsmokers (both *P*-interaction=0.01).

Conclusions: Higher IGF-1 concentrations are associated with a lower risk of COVID-19 mortality. Further studies are required to determine whether and

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

how targeting IGF-1 pathway might improve COVID-19 prognosis.

Abbreviations

COVID-19: coronavirus disease 2019; BMI: body mass index; MET, metabolic equivalent; ICD: international classification of diseases; OR: odds ratio; CI: confidence interval.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

An outbreak of Coronavirus Disease 2019 (COVID-19) began in December 2019 and has triggered a public health emergency of international concern [1]. The majority of COVID-19 patients have a self-limiting infection and recover, but some suffer severe symptoms and even die [2]. The suddenly deteriorating conditions of some patients are mainly attributed to systematic inflammatory injury caused by the excessive or uncontrolled activation of immune response, known as the cytokine storm, leading to respiratory distress syndrome (ARDS) and multiple organ failure [3].

Insulin-like growth factor 1 (IGF-1) belongs to the IGF family that plays a critical role in diverse biological activities including cell proliferation, metabolism, differentiation, and survival [4]. Cumulative evidence also supports that IGF-1 pathway can regulate the immune response via interaction with various cytokines (e.g., interferons) and immune cells such as T lymphocytes, macrophages, and bone marrow cells [5]. IGF-1 may act as an important switch controlling the amplitude and quality of the immune response [6]. Of note, IGF-1 administration is already an approved therapy for growth failure and may improve symptoms of autoimmune diseases such as type-1 diabetes and multiple sclerosis [7]. However, whether IGF-1 plays a role in COVID-19 prognosis remains unknown.

Therefore, in the current study, we used the UK Biobank resource, with recently released data on COVID-19 tests and updated death records, to

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

investigate the association between pre-diagnostic serum IGF-1 concentrations and mortality among COVID-19 patients.

Methods

Study Participants

UK Biobank is a prospective cohort study consisting of approximately half a million participants (aged 37-73 years) recruited across the UK between 2006 and 2010 [8]. Up to 22 May 2020, among 5516 participants who had undergone COVID-19 PCR tests provided by Public Health England, 1422 patients were diagnosed with COVID-19. In the current analysis, we also included additional 150 patients who died from COVID-19 according to the National Health Service death records. The patients who had no available data on serum IGF-1 (n=140) or died from other causes (n=7, including colon cancer, lung cancer, dementia, chronic ischaemic heart disease, and bronchopneumonia) were excluded, leaving 1425 patients in the final analysis.

Assessment of IGF-1

Details about serum biomarker measurements and assay performances have been described online (http://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf). Briefly, serum concentrations of IGF-1 were measured in UK Biobank's purpose-built facility using a 'one step sandwich' Chemiluminescent

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Immunoassay method based on DiaSorin Liaison XL Analyzer (Diasorin S.p.A), with a detection range of 1.3-195 nmol/L. The average coefficients of variation of IGF-1 derived from internal quality control samples of known high, medium, and low concentrations were 6.18%, 5.29%, and 6.03%, respectively. Moreover, the assay of serum IGF-1 was registered with an external quality assurance (EQA) scheme (RIQAS Immunoassay Speciality 1) to verify accuracy. The EQA results showed that 100% of participated distributions (n=105) were good or acceptable.

Ascertainment of COVID-19 Mortality

Dates and causes of death were obtained from death certificates held by the National Health Service Information Centre (England and Wales) and the National Health Service Central Register Scotland (Scotland) [9]. The outcome of current study was mortality due to COVID-19 (ICD-10 U07) and available death data were updated to 22 May 2020.

Ascertainment of Covariates

At baseline, participants attended one of 22 assessment centers across England, Scotland, and Wales where they completed a touch-screen, self-completed questionnaire. Ethnicity, smoking status, and alcohol intake were self-reported. Height and body weight were measured by trained nurses at baseline, and body mass index (BMI) was calculated as weight in kilograms

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

divided by height in meters squared. Townsend deprivation index was derived from residence using data on car and home ownership, unemployment, and household overcrowding. Physical activity was measured as total metabolic equivalent task-minutes per week for all activity including walking, moderate and vigorous activity.

Statistical Analysis

Because the date of COVID-19 testing did not represent the time of infection, the survival time for each patient could not be accurately estimated, leading to Cox regression models inapplicable in the current analysis. Therefore, we analyzed the association between IGF-1 and COVID-19 mortality using unconditional logistic regression models. Odds ratios (OR) and 95% confidence intervals (CI) for each quartile of IGF-1 were calculated, with the lowest quartile as the reference. Model 1 was adjusted for major covariates including age at infection, sex, and ethnicity; Model 2 was further adjusted for Townsend deprivation index, BMI, smoking status, alcohol drinking, and physical activity. We also additionally adjusted for C-reactive protein in those who had the inflammatory biomarker data (n=1418), and the results were essentially unchanged (data not shown).

Stratified analyses were conducted according to the median age at infection (<70, ≥70 years), sex (male, female), BMI (<30, ≥30 kg/m^2), physical activity (≤median, >median), and smoking status (never, ever) in the

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

fully-adjusted model. To investigate potential effect modification by these stratification variables, we used a likelihood ratio test comparing the models with and without interaction terms between IGF-1 concentrations and each of the stratification variables.

Sensitivity analyses were performed by excluding participants with baseline cancer or cardiovascular disease. We used SAS 9.4 for all analyses. All statistical tests were two-sided, and P <0.05 was defined as statistically significant.

Results

Among 1425 COVID-19 patients, 365 deaths occurred due to COVID-19. The median time from baseline blood draw to COVID-19 testing was 11.1 years (interquartile range: 10.5-11.8 years). The distribution of IGF-1 concentrations is shown in **Figure 1**, ranging from 4.79 to 46.09 nmol/L, which was similar to the distribution in the whole cohort (data not shown).

Table 1 summarizes the main characteristics of COVID-19 patients according to quartiles of serum IGF-1 concentrations. At baseline, participants with higher IGF-1 had a lower BMI and higher levels of physical activity, and tended to be younger, males, and nonsmokers.

As shown in **Table 2**, higher IGF1 concentrations were associated with a reduced risk of COVID-19 mortality in the multivariable models (Model 1, OR comparing quartile 5 verse 1: 0.58, 95% CI: 0.39-0.85, P-trend=0.01). The

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

association remained stable after further adjustment for the other confounders (Model 2, OR: 0.63, 95% CI: 0.43-0.93, *P*-trend=0.03).

Figure 2 shows the forest plot results of stratified analyses. The inverse associations of IGF-1 with a COVID-19 mortality were largely consistent across subgroups, except for sex and smoking status. The association appeared to be stronger in women and nonsmokers (both *P*-interaction=0.01).

Sensitivity analyses showed that the aforementioned associations remained basically unchanged after excluding 238 individuals who had baseline cancer or cardiovascular disease (**Table 3**).

Discussion

To the best of our knowledge, this study was the first to demonstrate an inverse association between pre-diagnostic circulating levels of IGF-1 and COVID-19 mortality risk among COVID-19 patients, particularly for women and nonsmokers. Our findings suggest that IGF-1 might play a role in COVID-19 prognosis.

Cytokine storm has been recognized as one of the major causes of ARDS and multiple organ failure in COVID-19 patients. Therefore, effectively suppressing the cytokine storm is important to prevent the disease deterioration and reduce COVID-19 mortality. Markedly elevated levels of circulating IL-6, IL-2R, IL-10, TNFα, etc. have been detected in patients with severe COVID-19 [10 11]. These cytokines are mainly produced by macrophages

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

and lymphocytes which have been implicated in cytokine storm [12]. Several studies in humans and animal models have suggested an anti-inflammatory effect of IGF-1. For example, there is an inverse relationship between circulating IGF-1 and IL-6 levels [13 14], and IGF-1/IGF binding protein-3 administration to severely burned patients effectively attenuated inflammatory effects and reduced IL-6 levels [15]. Recombinant human IGF-1 infusion into ApoE-deficient mice significantly decreased macrophage infiltration by downregulating IL-6 and TNF-α expression [16]. In addition, recombinant human IGF-1 can mediate autoimmune suppression in mouse models of autoimmune disease by increasing regulatory T cells in affected tissues [7]. However, it remains uncertain whether gender and smoking status modify the role of IGF-1 in immune regulation, and other studies also reported that IGF-1 might exert pro-inflammatory effects [17 18]. Future studies are necessary to clarify the mechanism of IGF-1 in COVID-19 prognosis.

Our study has several strengths. First, UK Biobank is a well-designed large cohort and are providing reliable data on COVID-19 diagnosis and related deaths, allowing us to do the analysis in a timely fashion. Second, biochemistry assays of IGF-1 were performed in a single dedicated central laboratory by a standard, reliable method and strict quality control procedures. Third, we were able to adjust for various covariates on demographic and lifestyle factors.

Several potential limitations also need to be acknowledged. First, the

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

observational nature of this study prevents us from inferring causality. However, our sensitivity analyses excluding baseline CVD and cancer supported the robustness of the findings. Second, given the lack of repeated IGF-1 measurements, we were unable to analyze the relationship between dynamic IGF-1 concentrations and COVID-19 mortality. However, we calculated the intraclass correlation coefficient (ICC) between IGF1 measurements collected 4 years apart in a subcohort (n= 16,356). The ICC value of 0.78, consistent with the previous data [19], indicates that IGF1 levels are generally stable over time. Third, due to limited coverage of coronavirus testing in the UK, ascertainment bias cannot be avoided. In addition, UK Biobank is not a representative sample of the UK population [20], limiting ability to generalize the results to the whole UK or other populations.

Conclusions

The current study indicates that higher serum IGF-1 concentrations are associated with a lower risk of COVID-19 mortality. Further studies are warranted to validate our findings and clarify underlying mechanisms.

Acknowledgments

We are grateful to UK Biobank participants. This research has been conducted using the UK Biobank resource under application number 52217.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Author Contributions

DH was responsible for the conception and design of the study. XF and DH had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. XF and CY did the statistical analysis and drafted the manuscript. JW, MY, HM, GJ, MS, ZH, and HS critically revised the manuscript for important intellectual content. All authors reviewed and approved the final manuscript.

References

1. Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents* 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924
2. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy* 2020 doi: 10.1111/all.14364
3. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. *J Infect* 2020;80(6):607-13. doi: 10.1016/j.jinf.2020.03.037
4. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. *Physiol Rev* 1996;76(4):1005-26. doi: 10.1152/physrev.1996.76.4.1005
5. Skarlis C, Nezos A, Mavragani CP, et al. The role of insulin growth factors in autoimmune diseases. *Annals of Research Hospitals* 2019;3
6. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? *Pharmacol Rev* 2010;62(2):199-236. doi: 10.1124/pr.109.002469
7. Bilbao D, Luciani L, Johannesson B, et al. Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. *EMBO Mol Med* 2014;6(11):1423-35. doi: 10.15252/emmm.201303376
8. Collins R. What makes UK Biobank special? *Lancet* 2012;379(9822):1173-4. doi: 10.1016/S0140-6736(12)60404-8
9. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015;12(3):e1001779. doi:

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

10.1371/journal.pmed.1001779

10. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020;130(5):2620-29. doi: 10.1172/JCI137244
11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
12. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. *Front Immunol* 2014;5:491. doi: 10.3389/fimmu.2014.00491
13. Rajpathak SN, McGinn AP, Strickler HD, et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. *Growth Horm IGF Res* 2008;18(2):166-73. doi: 10.1016/j.ghir.2007.08.004
14. Succurro E, Andreozzi F, Sciacqua A, et al. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects. *Diabetes Care* 2008;31(9):1886-8. doi: 10.2337/dc08-0553
15. Spies M, Wolf SE, Barrow RE, et al. Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. *Crit Care Med* 2002;30(1):83-8. doi: 10.1097/00003246-200201000-00013
16. Sukhanov S, Higashi Y, Shai SY, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. *Arterioscler Thromb Vasc Biol* 2007;27(12):2684-90. doi: 10.1161/ATVBAHA.107.156257
17. Li G, Zhou L, Zhang C, et al. Insulin-Like Growth Factor 1 Regulates Acute Inflammatory Lung Injury Mediated by Influenza Virus Infection. *Front Microbiol* 2019;10:2541. doi: 10.3389/fmicb.2019.02541
18. Wolters TLC, Netea MG, Hermus A, et al. IGF1 potentiates the pro-inflammatory response in human peripheral blood mononuclear cells via MAPK. *J Mol Endocrinol* 2017;59(2):129-39. doi: 10.1530/JME-17-0062
19. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. *Am J Epidemiol* 1997;145(11):970-6. doi: 10.1093/oxfordjournals.aje.a009065
20. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol* 2017;186(9):1026-34. doi: 10.1093/aje/kwx246

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure Legend

Figure 1. The distribution histogram of IGF-1 concentrations.

Figure 2. Forest plots of stratified analysis for the associations between serum IGF-1 concentrations and the risk of COVID-19 mortality.

Table 1. Baseline characteristics of COVID-19 patients according to quartiles of serum IGF-1 concentrations

	Serum IGF-1 concentrations, nmol/L			
Characteristic	Q1 (4.79-17.09)	Q2 (17.11-20.78)	Q3 (20.79-24.47)	Q4 (24.47-46.09)
Participants N	356	356	357	356
Age at blood draw, mean (SD), y	60.08 (7.33)	57.83 (9.24)	56.52 (9.29)	54.51 (9.36)
Age at infection, mean (SD), y	71.26 (7.39)	69.02 (9.36)	67.64 (9.32)	65.65 (9.32)
Female, No. (%)	180 (50.56)	168 (47.19)	168 (47.06)	150 (42.13)
White race, No. (%)	315 (88.48)	314 (88.20)	299 (83.75)	312 (87.64)
Body mass index, mean (SD), kg/m^2	29.88 (6.01)	29.20 (5.59)	28.52 (5.31)	27.90 (4.78)
Physical activity, mean (SD), MET-hours/w	37.08 (39.46)	42.98 (44.06)	43.73 (39.08)	47.96 (49.10)
Townsend deprivation index, No. (%)				
Low	102 (28.65)	104 (29.21)	140 (39.22)	134 (37.64)
Middle	118 (33.15)	135 (37.92)	115 (32.21)	107 (30.06)
High	136 (38.20)	117 (32.87)	102 (28.57)	115 (32.30)
Smoking status, No. (%)				
Never	139 (39.04)	167 (46.91)	176 (49.30)	186 (52.25)
Previous	167 (46.91)	146 (41.01)	134 (37.54)	124 (34.83)
Current	45 (12.64)	40 (11.24)	44 (12.32)	45 (12.64)
Alcohol consumption, No. (%)				
Daily to three times a week	119 (33.43)	134 (37.64)	109 (30.53)	119 (33.43)
Twice a week to once a month	114 (32.02)	140 (39.33)	142 (39.78)	150 (42.13)
Never or special occasions only	120 (33.71)	81 (22.75)	104 (29.13)	87 (24.44)

Abbreviations: MET, metabolic equivalent.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Association between serum IGF-1 concentrations and COVID-19 mortality

	Quartile of serum IGF-1 concentrations, OR (95% CI)				*P*-trend
	Q1 (4.79-17.09)	Q2 (17.11-20.78)	Q3 (20.79-24.47)	Q4 (24.47-46.09)	
No. of cases	122	95	86	62	
Model 1	ref	0.77 (0.55-1.09)	0.77 (0.54-1.09)	0.58 (0.39-0.85)	0.01
Model 2	ref	0.82 (0.58-1.17)	0.84 (0.59-1.21)	0.63 (0.43-0.93)	0.03

Model 1: adjusted for age at infection, sex, race. Model 2: adjusted for model 1 plus Townsend deprivation index, body mass index, smoking status, alcohol drinking, and physical activity. *P*-trend was based on the median value of each quartile of serum IGF-1 concentrations as a continuous variable in the models. Abbreviations: OR, odds ratio; CI, confidence interval; ref, reference.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 3. Association between serum IGF-1 concentrations and COVID-19 mortality after excluding participants with baseline cancer or cardiovascular disease (n=238)

	Quartile of serum IGF-1 concentrations, OR (95% CI)				*P*-trend
	Q1 (4.79-17.14)	Q2 (17.17-20.79)	Q3 (20.79-24.46)	Q4 (24.46-46.09)	
No. of cases	96	76	70	41	
Model 1	ref	0.83 (0.57-1.23)	0.86 (0.58-1.27)	0.52 (0.33-0.81)	0.01
Model 2	ref	0.88 (0.59-1.31)	0.95 (0.63-1.42)	0.58 (0.37-0.93)	0.047

Model 1: adjusted for age at infection, sex, race. Model 2: adjusted for model 1 plus Townsend deprivation index, body mass index, smoking status, alcohol drinking, and physical activity. *P*-trend was based on the median value of each quartile of serum IGF-1 concentrations as a continuous variable in the models. Abbreviations: OR, odds ratio; CI, confidence interval; ref, reference.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20149369; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .


20
15
10
5
0
percentage, %
5.0
7.5
10.0
12.5
15.0
17.5
20.0
22.5
25.0
27.5
30.0
32.5
35.0
37.5
40.0
42.5
45.0
Serum IGF-1 concentrations, nmol/L


Subgroup
Quartile
OR (95% CI)
P–interaction
Age at infection (years)
0.07
<70
1 ref
2 0.53 (0.25–1.13)
3 0.48 (0.22–1.02)
4 0.60 (0.28–1.28)
≥70
1 ref
2 0.97 (0.65–1.45)
3 1.06 (0.70–1.61)
4 0.67 (0.42–1.06)
Sex
0.01
Female
1 ref
2 0.65 (0.38–1.13)
3 0.66 (0.37–1.16)
4 0.44 (0.21–0.90)
Male
1 ref
2 1.01 (0.63–1.61)
3 1.07 (0.66–1.74)
4 0.81 (0.50–1.31)
BMI (kg/m²)
0.17
<30
1 ref
2 1.00 (0.63–1.60)
3 0.98 (0.62–1.56)
4 0.60 (0.36–1.00)
≥30
1 ref
2 0.67 (0.38–1.18)
3 0.63 (0.34–1.19)
4 0.67 (0.36–1.27)
Physical activity (MET-hour/week)
0.69
Below median
1 ref
2 0.51 (0.29–0.90)
3 0.81 (0.47–1.39)
4 0.66 (0.37–1.19)
Above median
1 ref
2 1.14 (0.71–1.82)
3 0.94 (0.57–1.54)
4 0.64 (0.38–1.10)
Smoking status
0.01
Never
1 ref
2 0.47 (0.26–0.85)
3 0.60 (0.34–1.07)
4 0.48 (0.26–0.91)
Ever
1 ref
2 1.16 (0.74–1.81)
3 1.11 (0.70–1.77)
4 0.78 (0.47–1.29)
0
0.5
1
1.5
2